The Company continues to expect total revenue for the fiscal year ending December 31, 2026 to approximate $890 million, representing growth of approximately $126 million, or 17% compared to full year 2025. This includes surgical revenue of approximately $805 million and EOS revenue of approximately $85 million. The Company is increasing its adjusted EBITDA guidance to approximately $134 million, or 15% of revenue, up from $130 million previously, reflecting continued operating leverage. The Company expects to generate at least $20 million of free cash flow for the full year 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- ATEC Upcoming Earnings Report: What to Expect?
- Alphatec: Procedure-Focused Spine Innovation and Enabling Technologies Support Profitable Growth and Multiple Expansion Upside
- Alphatec price target lowered to $20 from $27 at TD Cowen
- Top 5 Trending Stocks by Unusual Trading Volume, 1/13/26
- Alphatec: Strong Operational Momentum and 2026 Growth Outlook Support Buy Rating and $24 Target